Convergence: Toning down pain

Convergence, a GlaxoSmithKline spinout, focused on chronic pain

Convergence Pharmaceuticals Ltd. believes its state-dependent ion channel inhibitors can provide effective analgesia for chronic pain without the side effects associated with tonic ion channel blockers. On the back of a L22.4 million ($35.4 million) series A round, the company plans to start a Phase II trial for its lead molecule this year.

Convergence was spun out of GlaxoSmithKline plc this month after the pharma decided in

Read the full 660 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE